Universe Pharmaceuticals (NASDAQ:UPC – Get Free Report) and Scienture (NASDAQ:SCNX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.
Profitability
This table compares Universe Pharmaceuticals and Scienture’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Universe Pharmaceuticals | N/A | N/A | N/A |
| Scienture | N/A | -56.28% | -44.76% |
Earnings & Valuation
This table compares Universe Pharmaceuticals and Scienture”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Universe Pharmaceuticals | $17.86 million | 1.99 | -$3.67 million | N/A | N/A |
| Scienture | $430,000.00 | 39.17 | -$41.51 million | ($2.51) | -0.17 |
Universe Pharmaceuticals has higher revenue and earnings than Scienture.
Risk & Volatility
Universe Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, Scienture has a beta of 3.26, indicating that its stock price is 226% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and price targets for Universe Pharmaceuticals and Scienture, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Universe Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Scienture | 1 | 0 | 1 | 0 | 2.00 |
Scienture has a consensus target price of $1.50, suggesting a potential upside of 261.88%. Given Scienture’s stronger consensus rating and higher possible upside, analysts clearly believe Scienture is more favorable than Universe Pharmaceuticals.
Insider & Institutional Ownership
0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Comparatively, 21.4% of Scienture shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Scienture beats Universe Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Universe Pharmaceuticals
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji’An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
About Scienture
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
Receive News & Ratings for Universe Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Universe Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
